ClinicalTrials.gg
Drug

Pucotenlimab clinical trials

Also written HX008.

studies test it
52
open now
41
in phase 3
5
first study started
2018

How each study uses pucotenlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pucotenlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pucotenlimab
19

Development codes

HX008
12

In one entry with another drug

Given together, or one or the other

Pucotenlimab Combined with Lenvatinib
2
Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
2
MRG003+Pucotenlimab
2
Becotatug Vedotin and Pucotenlimab
2
Lenvatinib plus pucotenlimab
2
levima plus pucotenlimab
2

Studies by the year they started

51 studies that test it; most in 2026 (22); 1 more planned to start later

Studies that test pucotenlimab, by start year
YearStudies
20181
20192
20205
20211
20223
20233
20245
20259
202622

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
8
Phase 2
44
Phase 3
5
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 38

Sun Yat-sen University (13) · Taizhou Hanzhong biomedical co. LTD (10) · Fudan University (4) · Shanghai Zhongshan Hospital (2) · Sir Run Run Shaw Hospital (2) · Lepu Biopharma Co., Ltd. (2) · Jiyan Liu (2) · Tongji Hospital (2)

Often tested with

Tested in the same studies.

Becotatug vedotin (21) · Lenvatinib (7) · Trastuzumab vedotin (2) · Donafenib (1) · Folfox protocol (1) · Trifluridine tipiracil drug combination (1) · CAPOX Regimen (1) · Xelox (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 14

Studies that test pucotenlimab.

Studies

Open first, then newest update. How each study uses pucotenlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 52

See all 52 studies that test pucotenlimab →

Given beside what is tested · 10 — pucotenlimab is usual care or a partner of the new treatment

Codes

What other systems call pucotenlimab · ClinicalTrials.gg INT016225

  • UNII (FDA) CGA81G3KR5PUCOTENLIMABOne source FDA
  • NCI Thesaurus C160717PucotenlimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.